Biocytogen Pharmaceuticals, a global biotech innovator in antibody-based drug development, has announced a strategic partnership with Sihuan Pharmaceutical.

 

The agreement will combine Biocytogen’s cutting-edge fully human antibody discovery platform with Sihuan Pharmaceutical’s extensive drug development, manufacturing, and commercialization capabilities. The collaboration will target multiple disease areas, including weight loss, aiming to drive synergies and establish a long-term strategic alliance.

 

Sihuan Pharmaceutical praised the strength of Biocytogen’s technology platforms. Biocytogen will bring its proprietary target-humanized mouse models, in vivo efficacy systems, and AI-driven antibody discovery platform built on real human antibody sequences to the partnership, supporting the development of next-generation therapeutics.

 

Yuelei Shen, President and CEO of Biocytogen, said: “We are pleased to establish this strategic partnership with Sihuan Pharmaceutical. Leveraging our proprietary platforms, Biocytogen has built a comprehensive pipeline of next-generation therapeutic modalities, including bispecific and multispecific antibodies, ADCs, VHHs, and TCR-based therapeutics. This collaboration will further expand our joint efforts across diverse disease areas and further demonstrate strong industry recognition of our technology platforms.”

 

The partnership positions both companies to accelerate promising molecules towards clinical and commercial success.